Last year, the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the 14th Five-Year Plan" Period (hereinafter referred to as the "Guiding Opinions"), which proposed that by 2025, 5~10 specialized and diversified pharmaceutical retail chain enterprises of more than 50 billion yuan will be cultivated, and the annual sales of the top 100 pharmaceutical retail enterprises will account for more than 65% of the total pharmaceutical retail market, and the pharmaceutical retail chain rate will be close to 70%.
At that time, market analysis believed that retail chain pharmacies would continue to set off a wave of leapfrog development of mergers and acquisitions, while individual pharmacies would have a harder and harder time
.
In fact, this is true, because the higher the degree of chaining, the more conducive to supervision, in order to accelerate the development of retail pharmacy chain, many places have successively introduced relevant measures to support and encourage the province's drug retail chain operation, and promote the large-scale, intensive and standardized development
of drug retail operation.
For example, the Jiangxi Provincial Drug Administration recently issued the Opinions on Supporting the Development of Pharmaceutical Retail Chain Enterprises (Trial) (hereinafter referred to as the "Opinions"), launching 15 measures to support and encourage the development of
pharmaceutical retail chain enterprises in the province.
These measures focus on improving the drug retail chain rate and standardization level, focusing on supporting large wholesale enterprises and large pharmaceutical retail chain enterprise groups to integrate single pharmacies through various forms, allowing pharmaceutical retail chain enterprises to implement "multi-warehouse collaboration", and supporting the transfer of drugs between stores of the same retail chain enterprise as needed
.
The industry believes that with the implementation and implementation of the opinion, the chain rate of pharmacies in Jiangxi Province will continue to increase, while a large number of individual pharmacies will disappear
.
In addition to Jiangxi Province, Guangdong, Sichuan, Hebei and other provinces have also issued relevant documents
this year.
Among them, the Hebei Provincial Food and Drug Administration issued the "Opinions on Supporting the Development of Pharmaceutical Retail Chain Enterprises", which for the first time liberalized chain franchise and expressed support for pharmaceutical retail chain enterprises to integrate other pharmaceutical retail chain enterprises or single pharmacies
in the form of mergers, reorganizations, franchises, etc.
In addition, the "Guangdong Province Measures for the Supervision and Administration of Pharmaceutical Retail Chain Operation" officially implemented on May 1 also clarifies
the behavior and method of chain operation.
It is worth mentioning that in addition to vigorously supporting single pharmacy franchise chain enterprises in many places, large chains have also sent signals
to vigorously develop franchise business in recent years.
At present, large chains such as the common people and Da Shenlin have successively launched "new policies" to attract franchisees, covering various aspects
such as operation, capital, manpower and technology.
Benefiting from this, this year's listed chain has also achieved remarkable results in the expansion of franchise stores
.
It is reported that after the number of pharmacies exceeded 10,000 in the first half of this year, Yifeng Pharmacy also followed closely and is about to enter the "era of 10,000 stores"
.
On October 29, Yifeng Pharmacy released the third quarter report of 2022, which showed that from January to September 2022, the company added 2,116 stores; At the end of the reporting period, the total number of the company's stores was 9,781 (including 1,753 franchised stores).
In general, comprehensively improving the modernization level of drug circulation, improving the modern drug circulation system, improving the efficiency of drug circulation, and promoting the high-quality development of the industry are important starting points
for deepening the reform of the medical and health system and implementing the strategic decision of Healthy China in the new period of the 14th Five-Year Plan.
In this context, it is inevitable that
the retail pharmacy industry pattern will be further concentrated.
In the future, for retail enterprises, only by adhering to the development of characteristics, doing fine and specialized, and meeting the needs of the multi-level healthy consumer market can they continuously improve their competitiveness and not be easily eliminated
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];